{"id":796522,"date":"2024-12-20T09:04:41","date_gmt":"2024-12-20T14:04:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/"},"modified":"2024-12-20T09:04:41","modified_gmt":"2024-12-20T14:04:41","slug":"channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/","title":{"rendered":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">FREEHOLD, N.J., Dec.  20, 2024  (GLOBE NEWSWIRE) &#8212; Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical\u2019s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.<\/p>\n<p align=\"justify\">\u201cWe are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,\u201d said Eric Lang, Channel\u2019s Chief Medical Officer. \u201cWhile both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to moderate pain whereas an overexpression of NaV1.7 leads to debilitating pain morbidities, and we believe that NaV1.7 inhibition may be a more potent therapy for pain treatment.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Characteristics of Selective NaV1.7 Inhibition <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">NaV1.7 is a well-studied drug target with strong genetic validation \u2014 studies of inheritable pain disorders demonstrate that the spectrum of NaV1.7 activity validates the importance of this target.\n<\/li>\n<li style=\"text-align:justify\">Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing pain.<\/li>\n<\/ul>\n<p align=\"justify\">\u201cChannel Therapeutics has chosen a three-pronged approach for our NaV1.7 molecule to demonstrate the utility of this target. We are utilizing an oral NaV1.7 inhibitor for the potential treatment of neuropathic pain starting with Idiopathic Small Fiber neuropathy and Erythromelalgia, a novel eye drop formulation of a NaV1.7 inhibitor to treat eye pain and a novel slow-release depot formulation NaV1.7 inhibitor for post-surgical nerve blocks,\u201d stated Frank Knuettel II, Chief Executive Officer of Channel. \u201cThe important differences between NaV1.7 and NaV1.8 not only informs but also differentiates Channel Therapeutics\u2019 approaches to clinical development of the Company\u2019s selective sodium channel blockers <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K9II1aJYdNUt8Tf4NQNadKUMUoY0dGl5JZxPDfr7bbuJJoCMbzUVifVkXh4xKKV8NSKcWfJcQi1uaVjXWhgtHfh5t2ihRxQkAhbSIDSD6FQ=\" rel=\"nofollow\" target=\"_blank\">CC8464<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yRe8TQ2iwa3d09oMA9TqHgaUQplW4Ryt2yhSTaAprhBEsG5ZwfClEo6KeBEIfXAlA3lSSTu_6UQLNFU6r41bpIFMJcP1d6MsMkXAZKNcRU8=\" rel=\"nofollow\" target=\"_blank\">CT2000<\/a> and CT3000. We are very encouraged by the recent data that we have seen from our ongoing programs, including the results from our in vivo nerve block results published earlier this week. As such, we look forward to the upcoming studies and data readouts in 2025 which will serve as critical milestones for which to further substantiate the merits of Channel\u2019s clinical development plan,\u201d Mr. Knuettel concluded.<\/p>\n<p align=\"justify\">\n        <strong>About Channel <\/strong>\n      <\/p>\n<p align=\"justify\">Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company\u2019s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T4OzmJ_9RIpkcQQpxQuYT3rOdYyXhGBOBMMAH39XoQcS_oOV4-rssDnam2v3unqHMlJ82Sk46mEC_cYmKUw9l9TGuXfB_hszKvaMRPLM212QL_scXMLaj31NNEwHgqTH\" rel=\"nofollow\" target=\"_blank\">www.channeltherapeutics.com<\/a> or follow us on\u00a0social media.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements regarding the Company\u2019s current expectations. These forward-looking statements include, without limitation, references to the Company\u2019s expectations regarding (i) the Company\u2019s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company\u2019s belief the Company\u2019s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company\u2019s other programs, (iii) the Company\u2019s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company\u2019s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company\u2019s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company\u2019s Common Stock will be indicative of the Company\u2019s value or that the Company\u2019s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.<\/p>\n<p align=\"justify\">Channel Media and Investor Inquiries:<br \/>Mike Moyer<br \/>Managing Director, LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vBW2DhzZA-s_bFfgDprQifl2gtBllf6SSCHwIsDxyQwIOCa7bfxXSDBZucncrb1_Looi4lt3tsfOMXoSQK91f-_WuOP9tvd08ZI5AHVs5EWlpZNA-OJ0WKeQK8PHj9Lm\" rel=\"nofollow\" target=\"_blank\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmI1YmVkZDUtYzUyOC00Yzk3LTlhOTUtMTAzYmU2NWJkNmQyLTUwMDEyNjcxOQ==\/tiny\/Channel-Therapeutics-Corporati.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) &#8212; Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical\u2019s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. \u201cWe are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,\u201d said Eric Lang, Channel\u2019s Chief Medical Officer. \u201cWhile both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-796522","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) &#8212; Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical\u2019s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. \u201cWe are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,\u201d said Eric Lang, Channel\u2019s Chief Medical Officer. \u201cWhile both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to &hellip; Continue reading &quot;Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T14:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0\",\"datePublished\":\"2024-12-20T14:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/\"},\"wordCount\":793,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/\",\"name\":\"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\",\"datePublished\":\"2024-12-20T14:04:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/","og_locale":"en_US","og_type":"article","og_title":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk","og_description":"FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) &#8212; Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical\u2019s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. \u201cWe are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,\u201d said Eric Lang, Channel\u2019s Chief Medical Officer. \u201cWhile both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to &hellip; Continue reading \"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-20T14:04:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0","datePublished":"2024-12-20T14:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/"},"wordCount":793,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/","name":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==","datePublished":"2024-12-20T14:04:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMjQ5MCM2NjQ2NzE3IzUwMDEyNjcxOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=796522"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796522\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=796522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=796522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=796522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}